Stiles Financial Services Inc Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

Stiles Financial Services Inc raised its stake in Novo Nordisk A/S (NYSE:NVO) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,962 shares of the company’s stock after acquiring an additional 436 shares during the period. Novo Nordisk A/S makes up 1.9% of Stiles Financial Services Inc’s portfolio, making the stock its 9th biggest position. Stiles Financial Services Inc’s holdings in Novo Nordisk A/S were worth $5,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Winthrop Advisory Group LLC bought a new position in shares of Novo Nordisk A/S during the third quarter valued at $234,000. Lewis Asset Management LLC lifted its holdings in Novo Nordisk A/S by 3.4% in the third quarter. Lewis Asset Management LLC now owns 5,472 shares of the company’s stock valued at $652,000 after acquiring an additional 182 shares during the period. Channel Wealth LLC lifted its holdings in Novo Nordisk A/S by 15.6% in the third quarter. Channel Wealth LLC now owns 57,353 shares of the company’s stock valued at $6,829,000 after acquiring an additional 7,756 shares during the period. Portside Wealth Group LLC lifted its holdings in Novo Nordisk A/S by 3.9% in the third quarter. Portside Wealth Group LLC now owns 59,015 shares of the company’s stock valued at $7,027,000 after acquiring an additional 2,200 shares during the period. Finally, Consolidated Planning Corp lifted its holdings in Novo Nordisk A/S by 1.9% in the third quarter. Consolidated Planning Corp now owns 55,134 shares of the company’s stock valued at $6,565,000 after acquiring an additional 1,038 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $107.00 on Friday. The stock has a market capitalization of $480.17 billion, a PE ratio of 36.86, a P/E/G ratio of 1.43 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The business has a 50 day simple moving average of $122.65 and a two-hundred day simple moving average of $130.59. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, research analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.